These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 20942457)

  • 1. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.
    Milane L; Duan Z; Amiji M
    Mol Pharm; 2011 Feb; 8(1):185-203. PubMed ID: 20942457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer.
    Milane L; Duan ZF; Amiji M
    Nanomedicine; 2011 Aug; 7(4):435-44. PubMed ID: 21220050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.
    Milane L; Duan Z; Amiji M
    PLoS One; 2011; 6(9):e24075. PubMed ID: 21931642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment.
    Zhang Y; Tang L; Sun L; Bao J; Song C; Huang L; Liu K; Tian Y; Tian G; Li Z; Sun H; Mei L
    Acta Biomater; 2010 Jun; 6(6):2045-52. PubMed ID: 19969111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
    Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
    Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer.
    Cho H; Lai TC; Kwon GS
    J Control Release; 2013 Feb; 166(1):1-9. PubMed ID: 23246471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.
    Mattu C; Pabari RM; Boffito M; Sartori S; Ciardelli G; Ramtoola Z
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):463-72. PubMed ID: 23916461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer.
    Ren F; Chen R; Wang Y; Sun Y; Jiang Y; Li G
    Pharm Res; 2011 Apr; 28(4):897-906. PubMed ID: 21184150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
    Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
    Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
    Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model.
    van Vlerken LE; Duan Z; Little SR; Seiden MV; Amiji MM
    Mol Pharm; 2008; 5(4):516-26. PubMed ID: 18616278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
    Chavanpatil MD; Patil Y; Panyam J
    Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-installed polymeric nanocarriers for combination chemotherapy of EGFR-positive ovarian cancer.
    Xi X; Lei F; Gao K; Li J; Liu R; Karpf AR; Bronich TK
    J Control Release; 2023 Aug; 360():872-887. PubMed ID: 37478915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradable porous drug-loaded polymer scaffolds for localized cancer drug delivery and breast cell/tissue growth.
    Obayemi JD; Jusu SM; Salifu AA; Ghahremani S; Tadesse M; Uzonwanne VO; Soboyejo WO
    Mater Sci Eng C Mater Biol Appl; 2020 Jul; 112():110794. PubMed ID: 32409024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response.
    Tran BN; Nguyen HT; Kim JO; Yong CS; Nguyen CN
    Drug Dev Ind Pharm; 2017 Dec; 43(12):1952-1962. PubMed ID: 28724314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
    He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
    Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.
    van Vlerken LE; Duan Z; Seiden MV; Amiji MM
    Cancer Res; 2007 May; 67(10):4843-50. PubMed ID: 17510414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis.
    Wang X; Beitler JJ; Wang H; Lee MJ; Huang W; Koenig L; Nannapaneni S; Amin AR; Bonner M; Shin HJ; Chen ZG; Arbiser JL; Shin DM
    PLoS One; 2014; 9(2):e86369. PubMed ID: 24586249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo synergistic antitumor effect and safety of siRNA and lonidamine dual-loaded hierarchical targeted nanoparticles.
    Zhang BF; Xing L; Qiao JB; Cui PF; Wang FZ; Zhang JL; Xu CX; Jiang HL
    Int J Pharm; 2016 Jun; 506(1-2):207-13. PubMed ID: 27113867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.